Currently, there are 12.41M common shares owned by the public and among those 11.96M shares have been available to trade.
The company’s stock has a 5-day price change of 164.32% and 89.40% over the past three months. NKTR shares are trading 49.54% year to date (YTD), with the 12-month market performance up to 75.27% higher. It has a 12-month low price of $6.48 and touched a high of $22.79 over the same period. NKTR has an average intraday trading volume of 242.00K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 129.37%, 135.52%, and 72.87% respectively.
Institutional ownership of Nektar Therapeutics (NASDAQ: NKTR) 12.41M shares outstanding.
It has a market capitalization of $303.34M and a beta (3y monthly) value of 0.55. The earnings-per-share (ttm) stands at -$9.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 45.97% over the week and 23.11% over the month.
Analysts forecast that Nektar Therapeutics (NKTR) will achieve an EPS of -2.79 for the current quarter, -2.58 for the next quarter and -10.66 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -3.0 while analysts give the company a high EPS estimate of -3.0. Comparatively, EPS for the current quarter was -2.81 a year ago. Earnings per share for the fiscal year are expected to decrease by -19.62%, and -16.41% over the next financial year. EPS should shrink at an annualized rate of -16.75% over the next five years, compared to 25.49% over the past 5-year period.
Looking at the support for the NKTR, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 24, 2025, with the firm’s price target at $6.50-$120. BTIG Research coverage for the Nektar Therapeutics (NKTR) stock in a research note released on June 24, 2025 offered a Buy rating with a price target of $100. Jefferies was of a view on April 11, 2025 that the stock is Buy, while Oppenheimer gave the stock Outperform rating on March 14, 2025, issuing a price target of $6. B. Riley Securities on their part issued Buy rating on January 08, 2025.
